85329-89-1

Usage

Uses

Used in Pharmaceutical Industry:
(8beta)-N-[3-(dimethylamino)propyl]-N-(ethylcarbamoyl)-6-(prop-2-en-1-yl)ergoline-8-carboxamide phosphate (1:1) could be used as a pharmaceutical agent for the treatment of various disorders, given its ergoline core, which is known for its affinity to certain receptors in the body. The specific application would depend on the compound's pharmacological profile, which needs to be determined through further research.
Used in Research and Development:
In the field of scientific research, (8beta)-N-[3-(dimethylamino)propyl]-N-(ethylcarbamoyl)-6-(prop-2-en-1-yl)ergoline-8-carboxamide phosphate (1:1) may serve as a research tool for studying the interactions between ergoline-based molecules and their biological targets. It could be used to investigate receptor binding, signal transduction pathways, and other cellular processes relevant to drug discovery and development.
Used in Drug Delivery Systems:
As with other complex organic compounds, (8beta)-N-[3-(dimethylamino)propyl]-N-(ethylcarbamoyl)-6-(prop-2-en-1-yl)ergoline-8-carboxamide phosphate (1:1) might be employed in the development of drug delivery systems to improve the bioavailability and targeting of therapeutic agents, particularly if its pharmacological properties are found to be beneficial in treating specific conditions.

Upstream product

• 56741-94-7 2-amino-6-phenyl-3H-pyrimidin-4-one 
• 94-02-0 ethyl 3-oxo-3-phenylpropionate 
• 98-88-4 benzoyl chloride 
• 614-27-7 methyl 3-oxo-3-phenylpropionate 
• 93-58-3 benzoic acid methyl ester 
• 1402242-62-9 potassium trifluoro(3-oxo-3-phenylprop-1-yn-1-yl)borate 

Relevant academic research and scientific papers

Pyrimidin-6-yl Trifluoroborate Salts as Versatile Templates for Heterocycle Synthesis

We report a novel and general method to access a highly under-studied privileged scaffold—pyrimidines bearing a trifluoroborate at C4, and highlight the broad utility of these intermediates in a rich array of downstream functionalization reactions. This chemistry is underpinned by the unique features of the trifluoroborate group; its robustness provides an opportunity to carry out chemoselective reactions at other positions on the pyrimidine while providing a pathway for elaboration at the C?B bond when suitably activated.

Synthesis of 6-arylisocytosines and their potential for hydrogen bonding interactions

Abstract The synthesis of a number of 6-arylisocytosines, including linked bis-isocytosines, from the reaction of guanidine with β-ketoesters is described. The compounds were investigated for their ability to form hydrogen-bonded structural networks, and for their potential interactions with the telomeric quadruplex forming sequence AGGG(TTAGGG)3.

HTS followed by NMR based counterscreening. Discovery and optimization of pyrimidones as reversible and competitive inhibitors of xanthine oxidase

The identification of novel, non-purine based inhibitors of xanthine oxidase is described. After a high-throughput screening campaign, an NMR based counterscreen was used to distinguish actives, which interact with XO in a reversible manner, from assay artefacts. This approach identified pyrimidone 1 as a reversible and competitive inhibitor with good lead-like properties. A hit to lead campaign gave compound 41, a nanomolar inhibitor of hXO with efficacy in the hyperuricemic rat model after oral dosing.